Association of Free Vitamin D Concentrations and Asthma Treatment Failures in the VIDA Trial
Overview
Pulmonary Medicine
Authors
Affiliations
Background: Use of vitamin D serum concentrations as a biomarker of vitamin D status is questionable because of variation in vitamin D binding protein.
Objective: To determine associations between free vitamin D3 concentrations and rates of treatment failure and exacerbations in patients with asthma participating in the Vitamin D Add-on Therapy Enhances Corticosteroid Responsiveness in Asthma (VIDA) trial.
Methods: Free concentrations were directly measured by enzyme-linked immunosorbent assay and stratified into low, medium, and high groups: less than 5pg/mL (n = 65), 5 to 9pg/mL (n = 84), and greater than 9pg/mL (n = 48) after 12 weeks of supplementation with oral vitamin D3 and associated with outcomes.
Results: Outcomes did not associate with free concentrations: overall treatment failure rates were 0.60 (95% confidence interval [CI] 0.46-0.78), 0.53 (95%CI 0.40- 0.70), and 0.69 (95%CI 0.54-0.90)/person-year (P = .51), respectively; overall exacerbation rates were 0.28 (95%CI 0.17-0.48), 0.15 (95%CI 0.08-0.30) and 0.42 (95%CI 0.27-0.66)/person-year (P = .22). Mean (standard deviation) baseline free concentrations were lower in non-Hispanic blacks and Hispanics compared with non-Hispanic whites: 4.10 (1.33) and 4.38 (1.11) pg/mL vs 5.16 (1.65) pg/ml, (P < .001 and P = 0.038), respectively. Mean (standard deviation) baseline free concentrations differed between females and males: 4.57 (1.58) and 5.08 (1.41) (P = .026); and between non-overweight (body mass index [BMI] < 25) and overweight (BMI > 25): 5.45 (1.86) vs 4.54 (1.39) (P < .001). The free fraction differed by race and sex but not by BMI.
Conclusion: The use of free concentrations was inferior to total concentrations as a biomarker of efficacy of vitamin D supplementation in VIDA trial participants. Future studies of vitamin D status in patients with asthma should measure both free and total concentrations to better understand which marker of vitamin D function is most informative.
Therapeutic Potential of Vitamin D in Management of Asthma: A Literature Review.
Tibrewal C, Modi N, Bajoria P, Dave P, Rohit R, Patel P Cureus. 2023; 15(7):e41956.
PMID: 37588324 PMC: 10425698. DOI: 10.7759/cureus.41956.
Ishimine N, Wu S, Ota R, Takahashi K, Takiwaki M, Sugano M Biosci Rep. 2022; 42(10).
PMID: 36107130 PMC: 9547169. DOI: 10.1042/BSR20221326.
Asthma and Vitamin D Deficiency: Occurrence, Immune Mechanisms, and New Perspectives.
Salmanpour F, Kian N, Samieefar N, Tabari M, Rezaei N J Immunol Res. 2022; 2022:6735900.
PMID: 35874901 PMC: 9307373. DOI: 10.1155/2022/6735900.
Vitamin D Binding Protein and the Biological Activity of Vitamin D.
Chun R, Shieh A, Gottlieb C, Yacoubian V, Wang J, Hewison M Front Endocrinol (Lausanne). 2019; 10:718.
PMID: 31708871 PMC: 6821678. DOI: 10.3389/fendo.2019.00718.
Bjorkhem-Bergman L, Torefalk E, Ekstrom L, Bergman P BMC Res Notes. 2018; 11(1):619.
PMID: 30157946 PMC: 6114541. DOI: 10.1186/s13104-018-3725-7.